个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
首都医科大学附属北京朝阳医院,肿瘤科,主任医师,教授,硕士研究生导师
教育经历:
2016/09-2018/06,首都医科大学,肿瘤学,博士,导师:安广宇
2011/09-2014/06,首都医科大学,血液肿瘤学,硕士,导师:陈文明
1999/09-2004/06,首都医科大学,临床医学,学士
工作简历:
2022/07-至今,首都医科大学附属北京北京朝阳医院,肿瘤科,主任医师
2016/07-2022/07,首都医科大学附属北京北京朝阳医院,肿瘤科,副主任医师
2016/02-2016/06,首都医科大学附属北京北京朝阳医院,肿瘤科,主治医师
2015/06-2016/01, University of Oklahoma, Health Science Center, Research Scholar
2010/10-2015/05,首都医科大学附属北京北京朝阳医院,肿瘤科,主治医师
2007/08-2010/09,首都医科大学附属北京北京朝阳医院,肿瘤科,住院医师
2004/07-2007/07,首都医科大学附属北京北京朝阳医院,内科,住院医师
(1)国家自然科学基金青年项目,81802738,DCLK1与K-Ras/MAPKs通路相互作用推动胰腺癌发生发展的机制研究,2019/01-2021/12, 21万元,主持
(2)北京市自然科学基金面上项目,7202051,DCLK1抑制抗肿瘤免疫推动结直肠肿瘤发生的机制研究,2020/01-2022/12,主持
(3)国家自然科学基金面上项目,81572825, O-型糖基化异常在结肠癌发生和转移的机制研究,2016/01-2019/12,57万元,参加
(4)北京市青年骨干个人项目, 2016000021469G195,DCLK1及相关分子标志物的表达水平与结肠癌诊断及预后相关性的研究,2017/01-2018/12,主持
(5)首都医科大学自然科学培育基金,PYZ22095,DCLK1激活MAPK/ERK通路活化MDSCs诱导肠癌微环境免疫抑制的机制研究,2023/01-2023/12,主持
(1)Yan Rui#., Huang Xuying., Liu Heshu.,Xiao Zeru., Liu Jian., An Guangyu., Ge Yang*. DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma byRemodeling the Epithelial–Mesenchymal Transition Status. Biomedicines 2023, 11,1490.
(2)Liu Heshu#., Yan Rui., Xiao Zeru., HuangXuying., Yao Jiannan., Liu Jian., An Guangyu., Ge Yang*. Targeting DCLK1attenuates tumor stemness and evokes antitumor immunity in triple-negativebreast cancer by inhibiting IL-6/STAT3 signaling. Breast Cancer Res, 2023, 25:43.
(3)Yan Rui#. , Li Jianjian#., Xiao Zeru.,Fan Xiaona., Liu Heshu., Xu Ying., Sun Ruya., Liu Jian., Yao Jiannan., AnGuangyu., Shi Yan., Ge Yang*. DCLK1 Suppresses Tumor-Specific Cytotoxic TLymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis. CellMol Gastroenterol Hepatol, 2023, 15: 463-485.
(4)Ge Yang#*., Liu Heshu#., ZhangYuanyuan., Liu Jian., Yan Rui., Xiao Zeru., Fan Xiaona., Huang Xuying., AnGuangyu. Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transitionand restores T-cell activity in pancreatic ductal adenocarcinoma. Transl Oncol,2022, 17: 101317.
(5)Yan Rui#., Fan Xiaona#., Xiao Zeru#.,Liu Heshu., Huang Xuying., Liu Jian., Zhang Shucai., Yao Jiannan., An Guangyu.,Ge Yang*.Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas toEGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.Cancer Lett, 2022, 531: 83-97.
(6)Yao Jiannan., Duan Ling., Huang Xuying., Liu Jian., Fan Xiaona., Xiao Zeru., Yan Rui., Liu Heshu., An Guangyu., Hu Bin., Ge Yang*.(2021). Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma. Front Oncol, 11, 769727. doi:10.3389/fonc.2021.769727
(7)Ge Yang., Fan Xiaona., Huang Xuying., Weygant Nathaniel., Xiao Zeru., Yan Rui., Liu Heshu., Liu Jian., An Guangyu., Yao Jiannan.(2021). DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway. Mol Cancer Res, 19(12), 1980-1991. doi:10.1158/1541-7786.MCR-21-0161
(8)Ge Yang., Zhang Huiyun., Weygant Nathaniel., Yao Jiannan.(2021). Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol, 12(undefined), 640099. doi:10.3389/fphar.2021.640099
(9)Yan Rui., Li JianJian., Zhou Ying., Yao Li., Sun Ruya., Xu Ying., Ge Yang*., An Guangyu*.(2020). Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer. Life Sci, 241(undefined), 117150. doi:10.1016/j.lfs.2019.117150
(10)Ge Yang., Westphalen C Benedikt., Ma Wen Wee., Vega Kenneth J., Weygant Nathaniel.(2019). Implications for Tumor Microenvironment and Epithelial Crosstalk in the Management of Gastrointestinal Cancers. J Oncol, 2019(undefined), 4835318. doi:10.1155/2019/4835318
(11)Ge Yang., Kang Yi-Kun., Dong Li., Liu Li-Hong., An Guang-Yu.(2019). The efficacy of dietary Spirulina as an adjunct to chemotherapy to improve immune function and reduce myelosuppression in patients with malignant tumors. Transl Cancer Res, 8(4), 1065-1073. doi:10.21037/tcr.2019.06.13
(12)Ge Yang., Weygant Nathaniel., Qu Dongfeng., May Randal., Berry William L., Yao Jiannan., Chandrakesan Parthasarathy., Zheng Wei., Zhao Lichao., Zhao Karena L., Drake Michael., Vega Kenneth J., Bronze Michael S., Tomasek James J., An Guangyu., Houchen Courtney W.(2018). Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer, 143(5), 1162-1175. doi:10.1002/ijc.31400
#为第一作者,*为通讯作者
文件上传中...